Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY

Zoetis Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Black Titan Highlights Stablecoin Payment Networks’ Shift to Utilization and Machine-Native Commerce

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

ProPhase Labs Q2 FY26 Net Loss Narrows to $3 Million; Revenue Falls to $1 Million

Merck & Co. Inc. Stock Advances 12.6%, Outperforms Peers

Phibro Animal Health Updates Financial Calendar with Q4 and Full-Year Results Webcast and Conference Call

Merck upgraded to Overweight from Equal Weight at Morgan Stanley

Moderna's Cancer-Vaccine Breakthrough Drives Broad Biopharma Stock Rally

Royalty Pharma EVP and Chairman of Partnering Christopher Hite Sells 100,000 Shares for $6 Million

Kala Bio Q2 Net Loss Narrows to $1.58 Million from Year-Ago $11.16 Million

Enliven Therapeutics CMO Helen Louise Collins Reports Disposal of 5,000 Common Shares Worth $293,612.17

Hyperliquid Strategies Schedules Webcast on Fiscal 2026 Results

Crinetics Supplements Proxy Disclosures for Vertex USD 85-Per-Share Buyout After Shareholder Suits

Longeveron Names Nirav Jhaveri CFO, Replacing Interim Finance Chief Marie Washburn

Jaguar Health Inc: Q2 Total REV $1.2 Mln, EPS $-15.6

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role

Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan

Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)